Symptoms of endocrine treatment and outcome in the BIG 1-98 study

Breast Cancer Research and Treatment

Volumn 143, Issue 1, 2014, Pages 159-169

  Huober, J ^a,b,r   Cole, B F ^c,d   Rabaglio, M ^e,f   Giobbie Hurder, A ^d   Wu, J ^c   Ejlertsen, B ^g   Bonnefoi, H ^h   Forbes, J F ⁱ   Neven, P ^j   Lang I ^k   Smith, I ^l   Wardley, A ^m   Price, K N ^d,n   Goldhirsch, A ^o   Coates, A S ^e,p   Colleoni, M ^o   Gelber, R D ^d,n,q   Thurlimann B ^a,b  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^c University of Vermont   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e International Breast Cancer Study Group   (Switzerland)

^f UNIVERSITY OF BERN   (Switzerland)

^g Copenhagen University Hospital ^*  (Denmark)

^h INSTITUT BERGONIÉ   (France)

ⁱ UNIVERSITY OF NEWCASTLE   (Australia)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^k NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^l ROYAL MARSDEN HOSPITAL   (United Kingdom)

^m CHRISTIE HOSPITAL   (United Kingdom)

ⁿ FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^o EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^p UNIVERSITY OF SYDNEY   (Australia)

^q HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^r UNIVERSITY OF ULM   (Germany)

more..

Author keywords

Aromatase inhibitor; Breast cancer; Endocrine therapy; Side effects

Indexed keywords

LETROZOLE; TAMOXIFEN;

ADULT; AGED; ARTHRALGIA; ARTHRALGIA MYALGIA CARPAL TUNNEL SYMPTOM; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARPAL TUNNEL SYNDROME; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MYALGIA; POSTMENOPAUSE; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT DURATION; VASOMOTOR DISORDER;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NITRILES; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES; TUMOR BURDEN;

EID: 84892781922     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2792-7     Document Type: Article

References (36)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378:771-784
2. Regan MM, Neven P, Giobbie-Hurder A et al (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol 12:1101-1108
3. Cuzick J, Sestak I, Baum M et al (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer. 10-year analysis of the ATAC trial. Lancet Oncol 11:1135-1141
4. Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092
5. Simpson ER, Davis SR (2001) Minireview: aromatase and the regulation of estrogen biosynthesis-some new perspectives. Endocrinology 142:4589-4594
6. Gaillard S, Stearns V (2011) Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management. Breast Cancer Res 13:205
7. Stearns V, Johnson MD, Rae JM et al (2003) Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758-1764
8. Jin Y, Desta Z, Stearns V et al (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30-39
9. Borges S, Desta Z, Li L et al (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80:61-74
10. Amir E, Seruga B, Niraula S et al (2011) Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 103:1299-1309
11. Henry NL, Azzouz F, Desta Z et al (2012) Predictors of aromatase inhibitor discontinuation as a result of treatment-emergent symptoms in early-stage breast cancer. J Clin Oncol 30:936-942
12. Peréz-Soler R, Saltz L (2005) Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 23:5235-5246
13. Jubb AM, Harris AL (2010) Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 11:1172-1183
14. Anderson JR, Cain KC, Gelber RD (1983) Analysis of survival by tumor response. J Clin Oncol 11:710-719
15. Agresti A (2001) Exact inference for categorical data: recent advances and continuing controversies. Stat Med 20:2709-2722
16. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457-481
17. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Reports 50:163-170
18. Gray RJ (1988) A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154
19. Cox DR (1972) Regression models and life tables. J R Stat Soc B 34:187-220
20. Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509
21. Fleming TR, Harrington DP (1991) Counting processes and survival analysis. Wiley, New York, pp 147-148
22. Cuzick J, Sestak I, Cella D et al (2008) Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 9:1143-1148
23. van de Velde CJ, Rea D, Seynaeve C et al (2011) Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377:321-331
24. Hadji P, Kieback DG, Tams J et al (2012) Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM. Ann Oncol 23:2566-2572
25. Fontein DB, Seynaeve C, Hadji P et al (2013) Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis. J Clin Oncol 31:2257-2264
26. Stearns V, Chapman JW, Ma CX et al (2011) Relationship of treatment-emergent symptoms and recurrence-free survival in the NCIC CTG MA.27 adjuvant aromatase inhibitor trial. J Clin Oncol 29(31):4189-4198
27. Stearns V, Chapman JA, Ma C et al (2009) Treatment emergent symptoms and the risk of breast cancer recurrence in the NCIC CTG MA 27. Adjuvant aromatase inhibitor trial. Cancer Res 69(20):1489-1498
28. Mieog JSD, Morden JP, Bliss JM et al (2012) Carpal tunnel symptoms and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. Lancet Oncol 13:420-432
29. Park IH, Lee YS, Lee KS et al (2011) Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer. Cancer Chemother Pharmacol 68:1263-1271
30. Mao JJ, Su HI, Feng R et al (2011) Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer Res 13:R8
31. Ingle JN, Schaid DJ, Goss PE (2010) Genome-wide association and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 28:4674-4682
32. Mortimer JE, Flatt SW, Parker BA et al (2008) Tamoxifen, hot flashes and breast cancer recurrence. Breast Cancer Res and Treat 108:421-426
33. Regan MM, Leyland-Jones B, Bouzyk M et al (2012) CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst 104:441-451
34. Rae JM, Drury S, Hayes DF et al (2012) CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 104:452-460
35. Basch E, Jia X, Heller G et al (2009) Adverse symptom event reporting by patients versus clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101:1624-1632
36. Basch E, Iasonos A, McDonough T et al (2006) Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 7:903-909